title: Development and validation of a high-throughput screening assay for human long-chain fatty acid transport proteins 4 and 5.
abstract: Dietary long-chain fatty acid (LCFA) uptake across cell membranes is mediated principally by fatty acid transport proteins (FATPs). Six subtypes of this transporter are differentially expressed throughout the human and rodent body. To facilitate drugs discovery against FATP subtypes, the authors used mammalian cell lines stably expressing the recombinant human FATP4 and 5 and developed a high-throughput screening (HTS) assay using a 96-well fluorometric imaging plate reader (FLIPR). LCFA uptake signal-to-background ratios were between 3- and 5-fold. Two 4-aryl-dihydropyrimidinones, j3 and j5, produced inhibition of FATP4 with a half-maximal inhibitory concentration (IC(50)) of 0.21 and 0.63 microM, respectively, and displayed approximately 100-fold selectivity over FATP5. The US Drug Collection library was screened against the FATP5. A hit rate of around 0.4% was observed with a Z' factor of 0.6 +/- 0.2. Two confirmed hits are bile acids, chenodiol and ursodiol with an IC(50) of 2.4 and 0.22 microM, respectively. To increase throughput, a single time point measurement in a 384-well format was developed using the Analyst HT, and the results are comparable with the 96-well format. In conclusion, the FATP4 and 5 cell-based fluorescence assays are suitable for a primary drug screen, whereas differentiated cell lines are useful for a secondary drug screen.
authors.affiliation: Biosciences Division, SRI International, Menlo Park, CA 94063, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhou
authors.forename: Peter
authors.initials: P
authors.lastname: Madrid
authors.forename: Amy
authors.initials: A
authors.lastname: Fluitt
authors.forename: Andreas
authors.initials: A
authors.lastname: Stahl
authors.forename: Xinmin Simon
authors.initials: XS
authors.lastname: Xie
mesh_terms: D000818:Animals; D002460:Cell Line; D050612:Fatty Acid Transport Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005456:Fluorescent Dyes / Q000378:metabolism; D057166:High-Throughput Screening Assays / Q000379:methods*; D006801:Humans; D051379:Mice; D015394:Molecular Structure; D011744:Pyrimidinones / Q000737:chemistry / Q000378:metabolism; D015203:Reproducibility of Results
chemical_list: D050612:Fatty Acid Transport Proteins; D005456:Fluorescent Dyes; D011744:Pyrimidinones; C493571:SLC27A4 protein, human; C484819:SLC27A5 protein, human
references.citation: Gastroenterology. 2006 Apr;130(4):1259-69
references.pmid: 16618417
references.citation: Metabolism. 2006 Jan;55(1):8-12
references.pmid: 16324913
references.citation: Biochim Biophys Acta. 2004 Nov 8;1686(1-2):1-6
references.pmid: 15522816
references.citation: Pflugers Arch. 2004 Feb;447(5):722-7
references.pmid: 12856180
references.citation: Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E593-600
references.pmid: 11832362
references.citation: Curr Opin Lipidol. 2007 Jun;18(3):271-6
references.pmid: 17495600
references.citation: J Lipid Res. 2005 Mar;46(3):597-602
references.pmid: 15547301
references.citation: J Cell Biol. 2003 Jun 23;161(6):1105-15
references.pmid: 12821645
references.citation: Curr Opin Lipidol. 2005 Apr;16(2):173-8
references.pmid: 15767857
references.citation: J Lipid Res. 2008 Jan;49(1):230-44
references.pmid: 17928635
references.citation: J Biomol Screen. 1999;4(2):67-73
references.pmid: 10838414
references.citation: Anal Biochem. 2005 Jan 1;336(1):11-9
references.pmid: 15582553
references.citation: Arch Biochem Biophys. 2008 Sep 15;477(2):363-71
references.pmid: 18601897
references.citation: Bioorg Med Chem Lett. 2006 Jul 1;16(13):3504-9
references.pmid: 16644217
references.citation: Biochim Biophys Acta. 2005 Oct 1;1736(3):163-80
references.pmid: 16198626
references.citation: Prog Lipid Res. 2009 Jan;48(1):52-61
references.pmid: 19041341
references.citation: Eur J Med Res. 1996 Jan 19;1(4):176-80
references.pmid: 9386266
references.citation: Dev Cell. 2002 Apr;2(4):477-88
references.pmid: 11970897
references.citation: Trends Endocrinol Metab. 2001 Aug;12(6):266-73
references.pmid: 11445444
references.citation: Am J Physiol Endocrinol Metab. 2001 Jun;280(6):E1000-6
references.pmid: 11350782
references.citation: Am J Physiol. 1996 May;270(5 Pt 1):E873-81
references.pmid: 8967477
references.citation: Mol Cell. 1999 Sep;4(3):299-308
references.pmid: 10518211
references.citation: J Biol Chem. 2003 Dec 5;278(49):49512-6
references.pmid: 14512415
references.citation: Mol Cell Biochem. 2006 Mar;284(1-2):135-40
references.pmid: 16477381
references.citation: J Lipid Res. 2006 Mar;47(3):665-72
references.pmid: 16357361
references.citation: Gastroenterology. 2006 Apr;130(4):1245-58
references.pmid: 16618416
references.citation: Biochim Biophys Acta. 1998 Dec 22;1443(3):381-5
references.pmid: 9878842
references.citation: Front Biosci. 1997 May 15;2:d222-31
references.pmid: 9206980
references.citation: Diabetes Care. 2009 Nov;32 Suppl 2:S237-45
references.pmid: 19875558
references.citation: Proc Nutr Soc. 2004 May;63(2):259-62
references.pmid: 15294040
references.citation: J Biol Chem. 2003 May 2;278(18):16039-44
references.pmid: 12556534
references.citation: Assay Drug Dev Technol. 2007 Apr;5(2):191-203
references.pmid: 17477828
references.citation: Lipids. 2001 Sep;36(9):981-9
references.pmid: 11724471